Tokio Marine Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Tokio Marine Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14K	Buy	+188	New	+$13.2K	﹤0.01%	604

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Tokio Marine Asset Management's BBIO Position: Q2 2026 in Review

Tokio Marine Asset Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 188 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #604 among its holdings.

190 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Tokio Marine Asset Management held 188 shares of BridgeBio Pharma worth $14K as of Q2 2026.
BridgeBio Pharma was a new Tokio Marine Asset Management position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Tokio Marine Asset Management's portfolio in Q2 2026, its #604 holding.
190 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Tokio Marine Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.